JP2010536766A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536766A5
JP2010536766A5 JP2010521080A JP2010521080A JP2010536766A5 JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5 JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5
Authority
JP
Japan
Prior art keywords
hydrogen
phenyl
compound according
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521080A
Other languages
English (en)
Japanese (ja)
Other versions
JP5385904B2 (ja
JP2010536766A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/072049 external-priority patent/WO2009023453A1/en
Publication of JP2010536766A publication Critical patent/JP2010536766A/ja
Publication of JP2010536766A5 publication Critical patent/JP2010536766A5/ja
Application granted granted Critical
Publication of JP5385904B2 publication Critical patent/JP5385904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521080A 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤 Expired - Fee Related JP5385904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
US60/955,720 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2010536766A JP2010536766A (ja) 2010-12-02
JP2010536766A5 true JP2010536766A5 (OSRAM) 2011-09-22
JP5385904B2 JP5385904B2 (ja) 2014-01-08

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521080A Expired - Fee Related JP5385904B2 (ja) 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤

Country Status (11)

Country Link
US (1) US8188069B2 (OSRAM)
EP (1) EP2178844A1 (OSRAM)
JP (1) JP5385904B2 (OSRAM)
KR (1) KR101136260B1 (OSRAM)
CN (1) CN101778826B (OSRAM)
AU (1) AU2008287124B2 (OSRAM)
BR (1) BRPI0815135A2 (OSRAM)
CA (1) CA2694209C (OSRAM)
EA (1) EA017286B1 (OSRAM)
MX (1) MX2010001754A (OSRAM)
WO (1) WO2009023453A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
CN112359018A (zh) 2012-09-07 2021-02-12 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 1,4−ベンゾジアゼピノン化合物のプロドラッグ
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company N−置換ビス(フルオロアルキル)1,4−ベンゾジアゼピノン化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アルキル,フルオロアルキル−1,4−ベンゾジアゼピノン化合物
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company フルオロアルキルジベンゾジアゼピノン化合物
EP2981267A1 (en) 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
CN109310684B (zh) 2016-04-12 2021-11-19 伊莱利利公司 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向b細胞成熟抗原的多特異抗體之給藥方案及組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951466E (pt) * 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
EP1636196A1 (en) * 2003-03-14 2006-03-22 AstraZeneca AB Novel lactams and uses thereof

Similar Documents

Publication Publication Date Title
JP2010536766A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2010501534A5 (OSRAM)
JP2009149903A5 (OSRAM)
JP2010530897A5 (OSRAM)
JP2006526031A5 (OSRAM)
JP2007269812A5 (OSRAM)
JP2013505929A5 (OSRAM)
JP2010534247A5 (OSRAM)
JP2009541403A5 (OSRAM)
JP2011500769A5 (OSRAM)
JP2007522220A5 (OSRAM)
JP2013010749A5 (ja) カルバゾール化合物
JP2013507423A5 (OSRAM)
JP2011510079A5 (OSRAM)
JP2011512324A5 (OSRAM)
JP2013532130A5 (OSRAM)
JP2011227454A5 (OSRAM)
JP2007519721A5 (OSRAM)
JP2010520214A5 (OSRAM)
JP2014028916A5 (OSRAM)
JP2010508310A5 (OSRAM)
JP2010534246A5 (OSRAM)
JP2010500432A5 (OSRAM)
JP2010241791A5 (OSRAM)